-
Product Insights
NewNet Present Value Model: Caribou Biosciences Inc’s CB-010
Empower your strategies with our Net Present Value Model: Caribou Biosciences Inc's CB-010 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Thematic Analysis
RNA-Based Drugs and the Impact of COVID-19
This report investigates the past, current and future landscape of RNA-Based drugs, and how the success of the COVID-19 vaccines may have impacted this. High level analysis of the key trends and movements within the pharmaceutical industry in reference to RNA technology is provided, allowing you to identify and discern the key points within this area.
-
Product Insights
NewCytomegalovirus (HHV-5) Infections Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
GlobalData's clinical trial report, “Cytomegalovirus (HHV-5) Infections - Global Clinical Trials Review, 2024" provides an overview of Cytomegalovirus (HHV-5) Infections Clinical trials scenario. This report provides top line data relating to the clinical trials on Cytomegalovirus (HHV-5) Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 9MW-1111 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 9MW-1111 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. 9MW-1111 in Solid Tumor Drug Details: 9MW-1111 is under development for the...
-
Thematic Analysis
NewState of the Biopharmaceutical Industry 2024 Edition (Mid-Year Update) – Thematic Intelligence
Reasons to buy the ‘State of the Biopharmaceutical Industry 2024’ thematic intelligence report: Highlight the business environment and the industry, regulatory, and macroeconomic trends that are going to shape the biopharmaceutical industry in the next 12 months. Benchmark the impact of major themes on the biopharmaceutical industry in the next 12 months, Identify themes that will have the greatest positive or negative impact in the coming months. Comprehend the opinions of industry respondents on these themes. Predict the industry’s growth prospects...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Y-101D in Metastatic Hepatocellular Carcinoma (HCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Y-101D in Metastatic Hepatocellular Carcinoma (HCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Y-101D in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: Bi-specific...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amdizalisib in Splenic Marginal Zone B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Amdizalisib in Splenic Marginal Zone B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Amdizalisib in Splenic Marginal Zone B-Cell Lymphoma Drug Details:...
-
Company Insights
Innovation and Patenting activity of Moderna Inc Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Moderna Inc Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INBRX-106 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INBRX-106 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INBRX-106 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Linperlisib in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Linperlisib in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Linperlisib in Follicular Lymphoma Drug Details: Linperlisib (Intarel) is an antineoplastic agent....